Confidential, Same-Visit STI Testing for Pediatric and Adolescent Medicine

CDC and Medicaid guidelines call for annual chlamydia screening in sexually active female patients under 25.⁸ Send-out labs mean callback calls home that put patient privacy at risk and screening rates that fall short of the goal.

~30 min
Time to results1
Test and Treatment
In-visit
Lab Accurate
Results for ct/ng2

Same-Day Answers, Without the Phone Call

The binx io is an FDA-cleared, CLIA-waived, molecular point-of-care platform for chlamydia (CT) and gonorrhea (NG), delivering PCR-accurate results in approximately 30 minutes with no laboratory or lab-trained staff required.1,2,3 For pediatric and adolescent medicine practices, that means a confirmed result and treatment plan before the patient ever leaves the office.

THE PROBLEM WITH SEND-OUT TESTING

Lab Turnaround Times Are Costing You Patients

Send-out testing creates a multi-day window between testing and treatment, during which a significant share of adolescent patients never return and during which a callback can reach the wrong person entirely.

CENTRAL LAB WORKFLOW
  • 2-3 days of processing time⁶ Patient likely gone before results return
  • ~20% lost to follow-up⁴ Patients who never return for treatment or results
  • Empiric antibiotic use Treatment decisions often made without confirmed diagnosis, undermining stewardship⁵
  • Onward transmission risk Untreated patients continue spreading infection in the community
BINX IO WORKFLOW
  • ~30 minutes to result Same visit, same provider, same day
  • In-visit test results Reducing patients who never return for treatment
  • Targeted, confirmed treatment Diagnosis-driven prescribing supports antibiotic stewardship⁵
  • Supports screening compliance Confirmed, in-clinic results count toward adolescent chlamydia screening measures⁷
CLINICAL PERFORMANCE ²

Lab-Equivalent Accuracy in a Non-Lab Setting

Chlamydia Sensitivity / Specificity Gonorrhea Sensitivity / Specificity
Female 96.1% / 99.1% 100.0% / 99.9%
Male 92.5% / 99.3% 97.3% / 100.0%
Non-Laboratorians
94.8% of samples processed by non - laboratorians in a point-of-care setting¹
How it Works

It Fits Your Workflow

No lab staff, no certification, no complex setup. Fully automated with clear detected/not detected results, LIS/EMR integration, and an established reimbursement path for CT/NG point-of-care testing.

CLIA- Waived

CLIA- Waived

No laboratory certification required. Any trained staff member can operate the instrument in a point-of-care setting.
Connectable

Connectable

Ability to route directly into your existing systems. No manual transcription, no extra steps, no lag between result and clinical action.
Established reimbursement

Established reimbursement

CPT codes for CT/NG point-of-care testing are recognized by Medicare, Medicaid, and most commercial payers.

Supports HEDIS Performance⁷

Chlamydia screening is a nationally tracked HEDIS quality measure, based on the percentage of patients ages 16–24 who are sexually active and received at least one chlamydia test during the measurement period.⁷

Sources

1. Van Der Pol B, et al. Clinical Performance of the BD ProbeTec™ CT/GC Assay... [2,445-person multicenter study]. JAMA Network Open, 2020. https://doi.org/10.1001/jamanetworkopen.2020.4819 2. binx health io® CT/NG Assay Instructions for Use, MOB-ART-0700 v4.0, May 2022. 3. FDA 510(k) Summary, K191352. https://www.accessdata.fda.gov/cdrh_docs/pdf19/K191352.pdf 4. Schwebke JR, Sadler R, Sutton JM, Hook EW 3rd. Positive screening tests for gonorrhea and chlamydial infection fail to lead consistently to treatment of patients attending a sexually transmitted disease clinic. Sex Transm Dis 1997;24:181-184. https://pubmed.ncbi.nlm.nih.gov/9101628/ 5. Huntington S, Weston G, Adams E. Assessing the clinical impact and resource use of a 30-minute chlamydia and gonorrhoea point-of-care test at three sexual health services. Ther Adv Infect Dis, 2021. https://doi.org/10.1177/20499361211061645 6. Labcorp. Chlamydia/Gonococcus, NAA (Test 183194) — Result Turnaround Time. https://www.labcorp.com/tests/183194/chlamydia-gonococcus-naa 7. NCQA. Chlamydia Screening (CHL) — HEDIS Measure. https://www.ncqa.org/report-cards/health-plans/state-of-health-care-quality-report/chlamydia-screening-chl/ 8. CMS. Children's Health Care Quality Measures — Child Core Set. https://www.medicaid.gov/medicaid/quality-of-care/performance-measurement/adult-and-child-health-care-quality-measures/childrens-health-care-quality-measures